

UNITED STATES SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kurtz Ronald M MD</u> (Last) (First) (Middle) <u>C/O RXSIGHT, INC.</u> <u>100 COLUMBIA</u> (Street) <u>ALISO</u> <u>CA</u> <u>92656</u> <u>VIEJO</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>07/29/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>RxSight, Inc. [RXST]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>See Remarks</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>800,972</u>	<u>I</u>	<u>See footnote⁽¹⁾</u>

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Option (right to buy)</u>	<u>(2)</u>	<u>03/14/2027</u>	<u>Common Stock</u>	<u>2,299</u>	<u>4.34</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(3)</u>	<u>04/23/2030</u>	<u>Common Stock</u>	<u>40,335</u>	<u>15.09</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(4)</u>	<u>03/22/2031</u>	<u>Common Stock</u>	<u>96,805</u>	<u>15.6</u>	<u>D</u>	

Explanation of Responses:

1. Shares held by Cricklewood LP. The Reporting Person is the manager of the general partner of Cricklewood LP and shares voting and investment control of the general partner of Cricklewood LP with his spouse.

2. Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2015 Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 24, 2017. The option originally covered 570,000 shares of common stock pre 10.33 for 1 reverse split shares.

3. Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2015 Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 23, 2020. The option originally covered 500,000 shares of common stock pre 10.33 for 1 reverse split shares.

4. Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2015 Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 22, 2021.

Remarks:

President and Chief Executive Officer Exhibit 24 - Power of Attorney

/s/ Shelley Thunen, as
Attorney-in-Fact

07/29/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB

Number.

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of RxSight, Inc., Inc. (the "Company"), hereby constitutes and appoints Shelley Thunen and Martin J. Waters the undersigned's true and lawful attorneys-in-fact to:

1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agent shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 29th day of July, 2021.

Signature: /s/ Ron Kurtz, M.D.

Print Name: Ron Kurtz, M.D.
